You are in: eMedicine Specialties > Emergency Medicine > TRAUMA AND ORTHOPEDICS Fracture, FrontalArticle Last Updated: Mar 6, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Thomas Widell, MD, Vice Chairman, Assistant Professor, Department of Emergency Medicine, Rosalind Franklin School of Medicine/The Chicago Medical School, North Chicago, Illinois; Associate Residency Director, University of Chicago Emergency Medicine Program, Chicago, Illinois; Program Director Emergency Medical Education, Attending Physician, Mount Sinai Hospital Medical Center, Chicago, Illinois Editors: Francis Counselman, MD, Program Director, Chair, Professor, Department of Emergency Medicine, Eastern Virginia Medical School; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eric Legome, MD, Residency Director, Assistant Professor of Emergency Medicine, Department of Emergency Medicine New York University, New York University Hospital, Bellevue Hospital Center, Manhattan VA; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: frontal fracture, facial injuries, maxillofacial fractures, frontal bone fractures, supraorbital fractures, high-impact facial injuries, low-impact facial injuries, trauma injuries, facial fracture INTRODUCTIONBackgroundHippocrates described an array of facial injuries as long ago as 400 BC. In 1823, von Graeffe described an elastic tube placed in the nose to maintain an open airway. During the early 20th century, Sir Harold Gilles, father of plastic surgery, taught army personnel about breathing problems in patients with facial injuries and to place them supine to maintain an airway. René Le Fort, a Frenchman, studied cadavers in 1901. He described 3 basic types of fractures. Endotracheal anesthesia and radiography developed during the First World War led to a better understanding and treatment of facial fractures. During the Second World War, a multidisciplinary approach to treatment of facial fractures continued to improve the outcomes of severely injured soldiers. Advent of CT reconstruction of facial bones, along with new surgical techniques, has dramatically improved the final appearance patients who have sustained bony injuries. PathophysiologyMaxillofacial fractures result from blunt or penetrating injury. Blunt injuries are far more common, resulting from vehicular accidents, altercations, sporting-related trauma, occupational injuries, and falls. Penetrating injuries mainly are the result of gunshot wounds, stabbings, and explosions. Type of object striking the face and force behind the object are the main determinants of whether a person sustains soft-tissue or bony injury. In automobile accidents, striking a hard dashboard is more likely to cause bony injury than striking a padded dashboard or an airbag. Striking the steering wheel concentrates the force more than striking the flat surface of the dashboard. This also holds true for altercations with a bat, as compared to a bare fist or boxing glove. Penetrating injury from a shot gun at a distance is not likely to cause fractures. Bullets from low-velocity guns are likely to cause fractures; high-velocity bullets cause fractures and extensive soft-tissue damage. The amount of force needed to fracture different bones of the face has been studied; injuries have been divided into those that require high impact to fracture (greater than 50 times the force of gravity [g]) and those that require a low impact to fracture (50 g or less).
Frontal bone and supraorbital fractures require high-energy impact. Forces this strong may indicate intracranial injury. Frontal bone contains the frontal sinus, and fractures of only the anterior (outer) table or both anterior and posterior (inner) tables are possible. Associated fractures of the supraorbital ridge, nasoethmoidal complex, and other facial bones also may occur (see Fractures, Face). FrequencyUnited StatesApproximately 3 million facial injuries occur annually; however, most do not involve maxillofacial fractures. One study placed the incidence of severe maxillofacial injury (fractures and lacerations) at 0.04-0.09% for persons in motor vehicle accidents. Incidence of fractures due to motor vehicle injuries is higher in rural areas, and altercation-related fractures are more frequent in urban areas. Mortality/MorbidityIncidence of other major injuries is as high as 50% in high-impact fractures, while it is 21% for low-impact fractures. Motor vehicle accidents are more likely than violent altercations to cause other injuries. Mortality rate in high-impact fractures is as high as 12%, yet deaths rarely occur from maxillofacial injury. The incidence of cervical spine injuries associated with frontal fractures has been reported in the 0.2-6.0% range. SexAdult male-to-female ratio is 3:1. Consider domestic violence in women with facial injuries not related to a motor vehicle crash. AgeMale predominance is reduced to 2:1 in children. Consider child abuse when facial injuries are found in children. CLINICALHistory
Physical
DIFFERENTIALSBlast Injuries Corneal Abrasion Corneal Laceration Dislocations, Mandible Domestic Violence Epidural Hematoma Epistaxis Fractures, Cervical Spine Fractures, Face Fractures, Frontal Fractures, Mandible Fractures, Orbital Globe Rupture Neck Trauma Pediatrics, Child Abuse Retinal Detachment Sexual Assault Shock, Hemorrhagic Spinal Cord Injuries Subarachnoid Hemorrhage Subdural Hematoma
|
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | Usually DOC for treatment of mild to moderately severe pain, if no contraindications. Inhibits inflammatory reactions and pain, probably by decreasing activity of enzyme cyclooxygenase, which inhibits prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h prn; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn) |
|---|---|
| Description | Relieves mild to moderately severe pain. Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, which decreases prostaglandin synthesis. |
| Adult Dose | 500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | For relief of mild to moderately severe pain and inflammation. Administer small dosages initially to patients with small bodies, older persons, and those with renal or liver disease. Doses higher than 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1–1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in coagulation abnormalities or during anticoagulant therapy |
| Drug Name | Flurbiprofen (Ansaid, Ocufen) |
|---|---|
| Description | Has analgesic, antipyretic, and anti-inflammatory effects. May inhibit cyclooxygenase enzyme, inhibiting prostaglandin biosynthesis. |
| Adult Dose | 200-300 mg/d PO divided bid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effects of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants—monitor PT closely and instruct patients to watch for signs of bleeding; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
Pain control is essential to quality care. It ensures patient comfort, promotes pulmonary toilet, and aids physical therapy regimens. Many analgesics have sedating properties that benefit patients who have sustained fractures.
| Drug Name | Acetaminophen and codeine (Tylenol #3) |
|---|---|
| Description | Drug combination indicated for treatment of mild to moderately severe pain. |
| Adult Dose | 30-60 mg/dose based on codeine content PO q4-6h or 1-2 tab q4h; not to exceed 12 tab/d |
| Pediatric Dose | 0.5-1 mg/kg/dose based on codeine content PO q4-6h; 10-15 mg/kg/dose based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES) |
|---|---|
| Description | Drug combination indicated for relief of moderately severe to severe pain. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d of acetaminophen >12 years: 750 mg acetaminophen PO q4h; single dose not to exceed 10 mg of hydrocodone bitartrate; not to exceed 5 doses/d |
| Contraindications | Documented hypersensitivity; high-altitude cerebral edema; elevated intracranial pressure |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Oxycodone and acetaminophen (Percocet) |
|---|---|
| Description | Drug combination indicated for relief of moderately severe to severe pain. DOC for aspirin-hypersensitive patients. |
| Adult Dose | 1-2 tab/cap PO q4-6h prn |
| Pediatric Dose | 0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone |
| Contraindications | Documented hypersensitivity |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Duration of action may increase in elderly persons; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg/24 h of acetaminophen; higher doses may cause liver toxicity |
| Drug Name | Morphine sulfate (Duramorph, Astramorph, MS Contin) |
|---|---|
| Description | DOC for narcotic analgesia because of its reliable and predictable effects, safety, and ease of reversibility with naloxone. Morphine sulfate administered IV may be dosed in a number of ways and commonly is titrated until desired effect obtained. |
| Adult Dose | Starting dose: 0.1 mg/kg IV/IM/SC Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h Relatively hypovolemic patients: Start with 2 mg IV/IM/SC and reassess hemodynamic effects of dose |
| Pediatric Dose | Neonates: 0.05-0.2 mg/kg IV prn Children: 0.1-0.2 mg/kg IV q2-4h prn |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects; tricyclic antidepressants, MAOIs, and other CNS depressants may potentiate adverse effects |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Avoid in hypotension, respiratory depression, nausea, emesis, constipation, and urinary retention; caution in atrial flutter and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate |
Patients who may not have been immunized against Clostridium tetani products should receive tetanus immune globulin.
| Drug Name | Tetanus immune globulins (Hyper-Tet) |
|---|---|
| Description | For passive immunization of any person with a wound that may be contaminated with tetanus spores. |
| Adult Dose | For prophylaxis: 250-500 U IM in opposite extremity to tetanus toxoid For clinical tetanus: 3,000-10,000 U IM |
| Pediatric Dose | For prophylaxis: 250 U IM in opposite extremity to tetanus toxoid For clinical tetanus: 3,000-10,000 U IM |
| Contraindications | Since antibodies in globulin preparation may interfere with immune response to vaccination, do not administer within 3 mo of live virus immune globulin administration; may be necessary to revaccinate persons who received immune globulin shortly after live virus vaccination |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Persons with isolated IgA deficiency have potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA; do not perform skin testing since intradermal injection of concentrated gamma globulin may cause localized area of inflammation and can be misinterpreted, causing the medication to be withheld from a patient not allergic to this material; true allergic responses to human gamma globulin given in prescribed IM manner are extremely rare; do not admix with other medications since usually incompatible |
This agent is used for tetanus immunization. Booster injection in previously immunized individuals is recommended to prevent this potentially lethal syndrome.
| Drug Name | Tetanus toxoid |
|---|---|
| Description | Used to induce active immunity against tetanus in selected patients. Tetanus and diphtheria toxoids are the immunizing DOC for most adults and children >7 y. Necessary to administer booster doses to maintain tetanus immunity throughout life. Pregnant patients should receive only tetanus toxoid, not a diphtheria antigen-containing product. In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is midthigh laterally. |
| Adult Dose | Primary immunization: 0.5 mL IM, give 2 injections 4-8 wk apart and a third dose 6-12 mo after second injection Booster dose: 0.5 mL q10y |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; history of any type of neurological symptoms or signs following administration of this product FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are important cause of provocative poliomyelitis |
| Interactions | Patients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization due to poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent chloramphenicol since it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction is nevertheless clinically insignificant and does not preclude its concurrent use) |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use to treat actual tetanus infections, or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin) diminished antibody response to active immunization may be seen in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons recommended |
Article Last Updated: Mar 6, 2008